Clinically, it is intended to treat lung cancer patients with the EGFR/T790M drug-resistant mutation, which have undergone a phase III clinical trial in NSCLC in China (http://www.chinadrugtrials.org.cn/; Registration number: CTR20182519). This evidence concerns the gene EGFR and non-small cell lung carcinoma.